A latest case series reports on the use of CytoSorb therapy in 33 patients with liver dysfunction from Scharf and coworkers reports on a significant bilirubin reduction during CytoSorb treatment accompanied by significant decreases of AST, alanine aminotransferase and gamma-glutamyl transferase, reflecting an accompanying improvement in the overall liver function, as direct adsorption is unlikely due to molecular size of these substances (>64 kDa) (23). This evidence concerns the gene GPT and Decreased liver function.